BR9913242A - Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono - Google Patents

Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono

Info

Publication number
BR9913242A
BR9913242A BR9913242-7A BR9913242A BR9913242A BR 9913242 A BR9913242 A BR 9913242A BR 9913242 A BR9913242 A BR 9913242A BR 9913242 A BR9913242 A BR 9913242A
Authority
BR
Brazil
Prior art keywords
alpha
ethyl
treatment
iperidinamethanol
dimethoxyphenyl
Prior art date
Application number
BR9913242-7A
Other languages
English (en)
Inventor
Cesare Mondadori
Stephen M Sorensen
Janice M Hitchcock
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BR9913242A publication Critical patent/BR9913242A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"USO DE R(+)-ALFA-(2,3-DIMETOXIFENIL)-1-[2-(4-FLUOROFENIL)ETIL]-4-P IPERIDINAMETANOL PARA O TRATAMENTO DE DESORDENS DE SONO"<D>. Um método de tratamento de um paciente para uma Desordem de Sono compreendendo a administração de uma quantidade eficaz de R-(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametan ol ou um seu sal farmaceuticamente aceitável a um paciente que necessita de tal tratamento.
BR9913242-7A 1998-08-28 1999-07-29 Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono BR9913242A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14313598A 1998-08-28 1998-08-28
PCT/US1999/017331 WO2000012090A1 (en) 1998-08-28 1999-07-29 THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS

Publications (1)

Publication Number Publication Date
BR9913242A true BR9913242A (pt) 2001-05-15

Family

ID=22502745

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913242-7A BR9913242A (pt) 1998-08-28 1999-07-29 Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono

Country Status (32)

Country Link
EP (2) EP1105132B1 (pt)
JP (1) JP2002523460A (pt)
KR (3) KR100735513B1 (pt)
CN (1) CN1127954C (pt)
AT (1) ATE249830T1 (pt)
AU (1) AU764604B2 (pt)
BG (2) BG65416B1 (pt)
BR (1) BR9913242A (pt)
CA (2) CA2629396A1 (pt)
CZ (1) CZ300781B6 (pt)
DE (2) DE69941134D1 (pt)
DK (1) DK1105132T3 (pt)
EA (1) EA003791B1 (pt)
EE (1) EE04951B1 (pt)
ES (1) ES2204146T3 (pt)
HK (1) HK1040907B (pt)
HR (2) HRP20010140A2 (pt)
HU (1) HUP0202145A3 (pt)
ID (1) ID29601A (pt)
IL (2) IL141603A0 (pt)
ME (1) MEP20308A (pt)
MX (1) MXPA01002026A (pt)
NO (2) NO20010984L (pt)
NZ (1) NZ510083A (pt)
PL (1) PL195022B1 (pt)
PT (1) PT1105132E (pt)
SK (1) SK284858B6 (pt)
TR (1) TR200100670T2 (pt)
TW (1) TWI233802B (pt)
UA (1) UA74773C2 (pt)
WO (1) WO2000012090A1 (pt)
ZA (1) ZA200101466B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
WO2004009586A1 (en) 2002-07-19 2004-01-29 Biovitrum Ab Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169096A (en) 1985-07-02 1992-12-08 Merrell Dow Pharmaceuticals Inc. N-aralkyl-piperidine-methanol derivatives
US4877798A (en) * 1987-11-23 1989-10-31 Merrell Dow Pharmaceuticals Inc. Treatment of fibromyalgia
DE3888340T2 (de) * 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
WO1991018602A1 (en) 1990-06-01 1991-12-12 Merrell Dow Pharmaceuticals Inc. (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL
JPH05134149A (ja) * 1991-11-08 1993-05-28 Nippondenso Co Ltd 光半導体モジユール
US5618824A (en) * 1994-03-09 1997-04-08 Merrell Pharmaceuticals Inc. Treatment of obsessive-compulsive disorders with 5-HT2 antagonists
EP0796619A1 (en) * 1996-03-21 1997-09-24 Merrell Pharmaceuticals Inc. Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
US9702597B1 (en) 2016-02-18 2017-07-11 King Fahd University Of Petroleum And Minerals System and method for preventing absorbent crystallization in a continuously operating solar-powered absorption cooling system with hybrid storage

Also Published As

Publication number Publication date
DE69911436D1 (de) 2003-10-23
HK1040907B (zh) 2004-04-02
DK1105132T3 (da) 2003-11-24
EP1362589B1 (en) 2009-07-15
PT1105132E (pt) 2004-02-27
KR100764532B1 (ko) 2007-10-09
WO2000012090A1 (en) 2000-03-09
MXPA01002026A (es) 2003-03-27
MEP20308A (en) 2010-06-10
AU5135999A (en) 2000-03-21
CA2629396A1 (en) 2000-03-09
UA74773C2 (en) 2006-02-15
CA2341891A1 (en) 2000-03-09
NO20010984L (no) 2001-04-25
BG105289A (en) 2001-11-30
CN1127954C (zh) 2003-11-19
SK284858B6 (sk) 2006-01-05
EP1105132A1 (en) 2001-06-13
EA003791B1 (ru) 2003-10-30
HUP0202145A2 (hu) 2003-01-28
PL195022B1 (pl) 2007-08-31
HK1040907A1 (en) 2002-06-28
TR200100670T2 (tr) 2001-06-21
SK2692001A3 (en) 2001-07-10
BG65416B1 (bg) 2008-07-31
KR20010073026A (ko) 2001-07-31
IL141603A0 (en) 2002-03-10
BG109953A (en) 2007-12-28
CN1315861A (zh) 2001-10-03
KR20060023197A (ko) 2006-03-13
ATE249830T1 (de) 2003-10-15
TWI233802B (en) 2005-06-11
NO20091111L (no) 2001-04-25
EE200100122A (et) 2002-06-17
DE69941134D1 (de) 2009-08-27
AU764604B2 (en) 2003-08-21
CA2341891C (en) 2009-05-12
DE69911436T2 (de) 2004-07-01
ID29601A (id) 2001-09-06
ES2204146T3 (es) 2004-04-16
CZ2001726A3 (en) 2001-06-13
EP1105132B1 (en) 2003-09-17
EP1362589A1 (en) 2003-11-19
NO20010984D0 (no) 2001-02-27
EA200100201A1 (ru) 2001-08-27
IL141603A (en) 2006-08-20
EE04951B1 (et) 2008-02-15
ZA200101466B (en) 2002-05-21
HRP20010140A2 (en) 2002-02-28
HUP0202145A3 (en) 2003-02-28
JP2002523460A (ja) 2002-07-30
CZ300781B6 (cs) 2009-08-12
HRP20080389A2 (en) 2008-11-30
KR20060057029A (ko) 2006-05-25
KR100682799B1 (ko) 2007-02-15
KR100735513B1 (ko) 2007-07-06
PL346342A1 (en) 2002-02-11
NZ510083A (en) 2003-08-29

Similar Documents

Publication Publication Date Title
BR0110420A (pt) Agonistas muscarìnicos
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
PT867178E (pt) Utilizacao de agonistas nao alostericos de gaba para o tratamento de desordens do sono
DE69400799T2 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
EA200001010A1 (ru) Применение дексмедетомидина для седативного воздействия в отделении интенсивной терапии
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono
MY122477A (en) Sertraline oral concentrate
ATE214926T1 (de) Verwendung von (r-(z))-alpha-(methoxyimino)-alpha-(1-azabicycl (2.2.2.) oct-3-yl) acetonitril zur hemmung der amyloid-beta-a4-bildung bei der alzheimerschen krankheit
GEP20053512B (en) S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders.
DE60235965D1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
BR0003648A (pt) Composições e métodos para tratar condições alérgicas e inflamatórias com tosse
KR930007452A (ko) 벤조디아제핀-금단 환자의 불안증 치료방법
UY26735A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus
ECSP003771A (es) Metodo para prevenir la diarrea
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/445, A61P 25/20, A61P 11/00

Ipc: A61K 31/445 (2007.10), A61P 25/20 (2007.10), A61P

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ART. 8O, 11 E 13 DA LEI 9279 DE 14 DE MAIO DE 1996

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.